Long-term Outcomes for Acute Myeloid Leukemia Patients

A Survivorship Project to UnerstAnd and to impRove Long-Term Outcomes for Acute Myeloid Leukemia Patients (SPARTA): the Sparta Platform

This international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the general population.

Inclusion Criteria:

• Diagnosis of all subtypes of de novo AML, according to WHO criteria (at least 20% blasts in the bone marrow), except acute promyelocytic leukemia (APL).
• Age at AML diagnosis ≥ 18 years,
• Date of AML diagnosis at least 5 years before study enrollment,
• AML-free status at study enrollment,
• Written informed consent provided.

Exclusion Criteria:

• Major cognitive deficit or psychiatric problems hampering a self-reported evaluation,
• Not speaking and reading the language of the participating country,
• More than 75 years at the time of study enrollment,
• Receiving any active treatment for AML at the time of study enrollment.